MYC protein dysregulation is driven by BCR-PI3K signalling in diffuse large B-cell lymphoma
Author:
Affiliation:
1. Department of Pathology; Fudan University Shanghai Cancer Centre; Shanghai China
2. Department of Oncology; Shanghai Medical College; Fudan University; Shanghai China
3. Department of Pathology; the University of Chicago; Chicago IL USA
Funder
Science and Technology Commission of Shanghai Municipality
National Natural Science Foundation of China
Publisher
Wiley
Subject
General Medicine,Histology,Pathology and Forensic Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/his.13287/fullpdf
Reference26 articles.
1. Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab;Sud;Haematologica,2008
2. Clinical significance of MYC expression and/or ‘high-grade’ morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study;Cook;Am. J. Surg. Pathol.,2014
3. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP;Testoni;Br. J. Haematol.,2011
4. B-cell receptor signaling as a driver of lymphoma development and evolution;Niemann;Semin. Cancer Biol.,2013
5. SYK inhibition modulates distinct PI3K/AKT-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas;Chen;Cancer Cell,2013
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A Combination of CPI-0610 and SAHA Induces Apoptosis through STAT3 and p38 Signalling Pathways in Diffuse Large B-cell Lymphoma Cells;Current Medicinal Chemistry;2023-10-27
2. Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma;Frontiers in Immunology;2023-07-31
3. Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial;Blood Advances;2023-05-11
4. Development of a Prognostic Scoring System using MYC Expression and Soluble Interleukin Receptor -2 level for Diffuse Large B-cell Lymphoma;Yonago Acta Medica;2023
5. Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma;Drug Resistance Updates;2022-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3